NVS240517P97500
- 0.26
- 0.000.00%
Novartis AG Newsroom
Europe's Q1 earnings season ends: profits fell 6%, and “barely qualified” banks and pharmaceutical giants supported half of the country
The Zhitong Finance App learned that the strong performance of European banks and pharmaceutical giants helped push European companies' profits unexpectedly in the first quarter to exceed market expectations. Analysts believe that this also indicates that future performance guidelines may be further raised. According to Bloomberg Intelligence data, finance and healthcare are the only segments of the MSCI European Index with profitable growth, which is better than the decline in market expectations. Overall, the profit decline of 6% in the MSCI Europe Index (almost all constituent stocks reported results) was better than the general forecast of 11%. Bloomberg I
Express News | NYSE Order Imbalance 74976.0 Shares on Sell Side
MorphoSys Gains After Novartis Discloses All Tender Offer Conditions Were Met
Motor Neuron Disease Clinical Trial Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
New York, USA, May 16, 2024 (GLOBE NEWSWIRE) -- Motor Neuron Disease Clinical Trial Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight The
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE:PFE) and AstraZeneca Plc (NASDAQ:AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, j
Novartis Takeover Bid for MorphoSys Tops Minimum Acceptance Threshold
Novartis' (NOVN.SW) takeover offer surpassed the 65% minimum threshold as it was accepted by 79.6% of MorphoSys shareholders.
Novartis Meets All Tender Offer Conditions to Acquire MorphoSys for EUR 68 Per Share in Cash
Novartis Meets All Tender Offer Conditions to Acquire MorphoSys for EUR 68 Per Share in Cash
Voyager Therapeutics up 8% Following Quarterly Beats
European Buy-rated Stocks That Trade Cheaply Vs. Their U.S. Peers - UBS
Express News | NYSE Order Imbalance 64369.0 Shares on Sell Side
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
MacroGenics Inc (NASDAQ:MGNX) released interim data from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo).TAMARACK is being conducted in previously treated patients with metastatic
Express News | Novartis Gets FDA Breakthrough Designation For Scemblix
Express News | NYSE Order Imbalance 55282.0 Shares on Sell Side
Google DeepMind Develops Latest AI Model To Aid Scientists In Fighting Disease
Researchers at Alphabet Inc's (NASDAQ:GOOG) (NASDAQ:GOOGL) Google DeepMind have developed AlphaFold 3, an new artificial intelligence (AI) model.AlphaFold 3 can predict the structure and interactions
Cagent Vascular Appoints Chairman Brian Walsh to Expanded Role as Chief Executive Officer
Cagent Vascular announced today that Brian Walsh has been named Chief Executive Officer by the Cagent Vascular Board of Directors. He has served as Chairman of the Board since March 2018 and will continue in this
Questor: This Medical Stock Is Expensive – but Worth Paying for
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Radiopharma Stocks Higher as Sector Welcomes the Latest M&A Deal
Sector Update: Health Care Stocks Retreat Thursday Afternoon
Health care stocks were declining Thursday afternoon, with the NYSE Health Care Index shedding 0.6% and the Health Care Select Sector SPDR Fund (XLV) down 0.2%. The iShares Biotechnology ETF (IBB) ros
Novartis to Pay up to $1.75 Billion for U.S. Cancer-focused Biotech
By Steve Goldstein Pharmaceutical giant Novartis AG on Thursday said it will pay up to $1.75 billion for a U.S. biotech focused on cancer. Novartis said it's paying $1 billion upfront and up to $750